论文信息 - Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors - 字舞流文

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

G. Manikhas | S. Tjulandin | U. Keilholz | V. Semiglazov | V. Moiseyenko | M. Learoyd | M. Stuart | A. Saunders | Sergei Tjulandin